Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Bayer : Brazil agency says Bayer-Monsanto tie-up can hurt competition, urges conditions

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 08:41pm CEST
FILE PHOTO: Monsanto logo is displayed on a screen where the stock is traded on the floor of the NYSE

SAO PAULO (Reuters) - A unit of Brazil's competition regulator Cade has said Bayer AG's (>> Bayer) proposed takeover of Monsanto Co. (>> Monsanto) could be detrimental to competition and urged conditions for Brazilian approval of the corporate tie-up, a document released on the agency's website shows.

SAO PAULO (Reuters) - A unit of Brazil's competition regulator Cade has said Bayer AG's (>> Bayer) proposed takeover of Monsanto Co. (>> Monsanto) could be detrimental to competition and urged conditions for Brazilian approval of the corporate tie-up, a document released on the agency's website shows.

The Bayer-Monsanto transaction, announced in September 2016, would create the world's largest integrated pesticides and seeds company.

The Cade unit said that anticipated merger-related efficiencies were insufficient to mitigate its competition concerns, according to the document dated Oct. 3.

It recommended what it termed as "structural solutions" as a condition for final approval the deal, which will be in the hands of Cade's seven-member tribunal.

Cade has 330 days to make a final decision since it began its review of the deal on April 24, a spokesman for the agency said. However, he added it may announce a ruling as early as Dec. 20.

The Cade unit said solutions included creating or strengthening another player to compete in the markets for soy and cotton seeds and in the sphere of biotech development.

But the unit has not engaged in an in-depth discussion with Bayer and Monsanto related to its suggested "remedies," the document said.

In an emailed statement to Reuters, Bayer said the unit's opinion is non-binding and does not mean the transaction will be blocked.

Hugh Grant, Monsanto's chief executive officer, said concerns expressed by Brazil's regulator are a normal step in the review process.

Brazil is Monsanto's biggest market outside of the United States.

In its second-quarter results, Bayer said sales of its crop science division tumbled more than 15 percent primarily because of its business in Brazil, an indication of the country's weight as a market for seed technology, insecticides and herbicides.

Deal opponents have asked Cade to block it or force divestments including Monsanto's Intacta RR2 IPRO soy seed technology and Bayer's glufosinate ammonium herbicides.

Last week, Monsanto's chief executive officer for South America, Rodrigo Santos, told Reuters the company was set on keeping rights to Intacta.

Cotton farmers against the transaction assert the merged company would control 14 out of 15 genetically modified cotton seed technologies available in Brazil.

If Cade orders asset disposals from the companies, authorities must see to it that the buyer is a relevant player in the biotech, seed production and crop defence segments, said attorney Rachel Mendonça, a partner at Mendonça e Nogueira Advogados.

Her law firm is representing three industry groups opposing the deal.

(Reporting by Ana Mano; editing by Alexander Smith and W Simon)

By Ana Mano

Stocks treated in this article : Monsanto, Bayer
Stocks mentioned in the article
ChangeLast1st jan.
MONSANTO 0.00%-End-of-day quote.9.57%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
01:29aBAYER : Financial Risk Management Software Market valued at US$ 7.04 billion in ..
AQ
01:22aBAYER : Dental Drugs Market valued at US$ 4.25 Mn in 2017 and is expected to rea..
AQ
06/22BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
EQ
06/22BAYER : Demonstrates Its Commitment to Human Rights
AQ
06/21BAYER : Findings from Bayer Update Understanding of Cardiovascular Agents (Clini..
AQ
06/21BAYER : Recent Findings from Bayer Provides New Insights into Chemical Modeling ..
AQ
06/21STUDY DATA FROM BAYER UPDATE UNDERST : A Small-Molecule Oral HIF-Prolyl Hydroxyl..
AQ
06/21BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
EQ
06/21BAYER : Issues New Bonds With a Volume of 15 Billion U.S. Dollars
AQ
06/21BAYER : supports a new UN code opposing discrimination against lesbian, gay, bis..
PU
More news
News from SeekingAlpha
06/21American Vanguard buys Bromacil herbicide assets from Bayer 
06/20SA INTERVIEW : Chris DeMuth Jr. On First United And ETF Reconstitutions 
06/19Can-Fite up 14% premarket on encouraging mid-stage Namodenoson data 
06/13Biotech industry group criticized for party featuring topless dancers 
06/11Merck KGaA's tepotinib successful two mid-stage liver cancer studies 
Financials (€)
Sales 2018 39 085 M
EBIT 2018 7 631 M
Net income 2018 5 385 M
Debt 2018 32 174 M
Yield 2018 2,88%
P/E ratio 2018 18,32
P/E ratio 2019 17,04
EV / Sales 2018 3,14x
EV / Sales 2019 2,56x
Capitalization 90 364 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 116 €
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-5.82%105 076
JOHNSON & JOHNSON-12.27%327 330
PFIZER0.00%213 275
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
MERCK AND COMPANY8.90%164 862